Evidence map›Paper›PMID 42367813›Full record

ArticleFrontiers in immunology2026

PD-L1-centric whole blood-based immune signature profiles of tuberculosis patients during therapy.

Johanna Eggeling, Martina Sester, Christoph Lange, Jan Heyckendorf, Barbara Kalsdorf, Anna M Mandalakas, Andrew R DiNardo, David Lewinsohn, Dagmar Schaub, Tina Schmidt and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Johanna Eggeling *Research Center Borstel, Leibniz Lung Center, Division of Clinical Infectious Diseases, Borstel, Germany.
Martina Sester *Department of Transplant and Infection Immunology, Saarland University, Homburg, Germany.
Christoph Lange *Research Center Borstel, Leibniz Lung Center, Division of Clinical Infectious Diseases, Borstel, Germany.
Jan HeyckendorfSchleswig-Holstein University Hospital, Internal Medicine I, Leibniz Lung Clinic, Kiel, Germany.
Barbara Kalsdorf *Research Center Borstel, Leibniz Lung Center, Division of Clinical Infectious Diseases, Borstel, Germany.
Anna M Mandalakas *Research Center Borstel, Leibniz Lung Center, Division of Clinical Infectious Diseases, Borstel, Germany.
Andrew R DiNardo *Global Tuberculosis Program, Division of Global Health, Baylor College of Medicine and Texas Children´s Hospital, Houston, TX, United States.
David Lewinsohn *Pulmonary, Allergy and Critical Care Medicine, Oregon Health and Science University, Portland, OR, United States.
Dagmar Schaub *Research Center Borstel, Leibniz Lung Center, Division of Clinical Infectious Diseases, Borstel, Germany.
Tina Schmidt *Department of Transplant and Infection Immunology, Saarland University, Homburg, Germany.
Eva Tolosa *Institute of Immunology, Hamburg Center for Translational Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Maja Reimann *Research Center Borstel, Leibniz Lung Center, Division of Clinical Infectious Diseases, Borstel, Germany.
Patricia M Sánchez Carballo *Research Center Borstel, Leibniz Lung Center, Division of Clinical Infectious Diseases, Borstel, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This prospective study investigated whole blood-based immune cell biomarkers for pulmonary tuberculosis (TB) immunoprofiling. Blood samples from 34 healthy controls and 51 tuberculosis patients were analyzed at three timepoints: Prior to therapy (T0), after 14 days of therapy (T1), and at the end of treatment (Te). Using multiparameter flow cytometry, 386 immune cell populations were analyzed. Predictive models were developed using two machine learning algorithms. A TB5

Indexed as

B7-H1 AntigenTuberculosis, PulmonaryAdultAntitubercular AgentsBiomarkersFemaleFlow CytometryHumansMaleMiddle AgedNeutrophilsProspective StudiesTh1 CellsAntitubercular AgentsB7-H1 AntigenBiomarkersCD274 protein, humanbiomarkerflow cytometryinfectious diseasemachine learningpersonalized medicineprogrammed cell death ligand 1risk assessment

Identifiers

PMID42367813
PMCPMC13305727

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.